市場調查報告書
商品編碼
1004487

靜脈內免疫球蛋白的全球市場 (2020年∼2027年)

Global Intravenous Immunoglobulin Market - 2020-2027

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

隨著獲得性和原發性免疫缺陷等疾病的流行,靜脈注射免疫球蛋白 (IVIG) 的全球市場預計將繼續擴大。許多公司都在參與新藥的開發和臨床試驗,也正在製定向世界各地擴張、擴大產品組合等戰略。從地區來看,在北美國家在全球市場上處於領先地位的同時,亞太地區也經歷了顯著的市場增長。

本報告提供全球靜脈內免疫球蛋白的市場相關分析,提供市場規模趨勢預測,及各給藥途徑·各臨床實驗階段·各終端用戶·各用途·各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介等相關調查。

目錄

第1章 全球靜脈內免疫球蛋白市場:分析方法·範圍

第2章 全球靜脈內免疫球蛋白市場:市場定義和概要

第3章 全球靜脈內免疫球蛋白市場:摘要整理

第4章 全球靜脈內免疫球蛋白市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球靜脈內免疫球蛋白市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求
  • 專利趨勢

第6章 全球靜脈內免疫球蛋白市場:新型冠狀病毒感染疾病 (COVID-19)的分析

  • COVID-19對市場的影響分析
    • "COVID-19前" /過去的市場方案
    • "COVID-19中" /目前市場方案
    • "COVID-19後" /未來市場方案
  • COVID-19疫情中的價格趨勢
  • 需求與供給的變動階段
  • 感染擴大時政府的市場相關配合措施
  • 各製造公司的策略展開情形
  • 結論

第7章 全球靜脈內免疫球蛋白市場:各給藥途徑

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各給藥途徑
  • 市場向心力指數:各給藥途徑
    • 靜脈內
    • 皮下

第8章 全球靜脈內免疫球蛋白市場:各臨床實驗階段

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各臨床實驗階段
  • 市場向心力指數:各臨床實驗階段
    • 免疫球蛋白G
    • 免疫球蛋白A
    • 免疫球蛋白M
    • 免疫球蛋白E
    • 免疫球蛋白D

第9章 全球靜脈內免疫球蛋白市場:各終端用戶

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各終端用戶
  • 市場向心力指數:各終端用戶
    • 醫院
    • 診所
    • 居家醫療
    • 其他

第10章 全球靜脈內免疫球蛋白市場:各用途

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各用途
  • 市場向心力指數:各用途
    • 低伽馬球蛋白血症
    • 慢性發炎性去髓鞘化性多發神經病變 (CIPD)
    • 免疫力缺乏症
    • 重症肌無力
    • 多病灶性運動神經病變 (MMN)
    • 特發性血小板減少紫斑症 (ITP)
    • 發炎性筋疾病
    • 特定抗體缺損症
    • 吉蘭-巴利症候群
    • 其他

第11章 全球靜脈內免疫球蛋白市場:各地區

  • 簡介
  • 市場規模和與前一年同期相比成長率 (YoY):各地區
  • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模·與前一年同期相比成長率 (YoY):各給藥途徑
    • 市場規模·與前一年同期相比成長率 (YoY):各臨床實驗階段
    • 市場規模·與前一年同期相比成長率 (YoY):各終端用戶
    • 市場規模·與前一年同期相比成長率 (YoY):各用途
    • 市場規模·與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第12章 全球靜脈內免疫球蛋白市場:競爭情形

  • 競爭方案
  • 市場定位/佔有率分析
  • 企業合併·收購 (M&A)的分析

第13章 全球靜脈內免疫球蛋白市場:企業簡介

  • Bharat Serums and Vaccines Limited
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Biotest AG
  • China Biologic Products, Inc.
  • Guizhou Taibang Biological Products Co., Ltd
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG

第14章 全球靜脈內免疫球蛋白市場:重要考察

第15章 關於DataM Intelligence

目錄

Market Overview

Immunoglobulin refers to the breakdown of blood plasma that contains antibodies. Intravenous immunoglobulin (IVIG) is defined as a blood product administered intravenously. This therapy is for individuals who cannot produce an adequate number of antibodies. Intravenous immunoglobulin therapy treats patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia, and other forms of hypogammaglobulinemia.

The global intravenous immunoglobulin market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Factors such as fast changing lifestyles such as sedentary habits, including consumption of salt, sugars and saturated fats, reduced physical activities, and increase in alcohol consumption has led to risinf prevalence of diseases such as acquired and primary immunodeficiency diseases. IVIG therapies being one of the most effective & the only available treatment option for such diseases is anticipated to fuel the intravenous immunoglobulin market growth during the forecast period.

The demand for for the treatment of is rapidly increasing as it is the. The increasing prevalence of lifestyle-associated disorders such as obesity & antibody deficiency disorders are the factors

Increase in primary immune deficiency diseases to drive the intravenous immunoglobulin market

Increasing cases of primary immune deficiency diseases is expected to drive the demand for fast, accurate, and safe treatment options, thus augmenting the market growth. Furthermore, Increasing occorance of dieseases, such as organ transplantation, neurological disorders, peripheral neuropathies, and Alzheimer's disease are expected to provide growth opportunities to the intravenous Immunogl (IVIG) market players. Thus, growing cases of the aforementioned diseases are expected to increase the penetration of IVIG during the forecast period.

Increase in Research and Development

Many companies are actively involved in R&D for the development of innovative drugs and discovering new therapeutic areas for the existing drugs. In August 2017, Kedrion Biopharma, Inc. and Kamada Ltd. received approval from the U.S. FDA for their new product KEDRAB. Promeinent industry players are emphesizing in the development of new plasma collection centers and other collaborative strategies to expand their geographical reach and widen their product portfolio.

COVID-19 Impact Analysis

COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has impacted the manufacturers' supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. Also, the pandemic is expected to have a positive impact on the growth of the intravenous immunoglobulin market globally. The market for immunoglobulin therapies is expected to spike during the pandemic and, thus drive the intravenous immunoglobulin market during the forecast period.

Segment Analysis

Based on the application, the Intravenous Immunoglobulin market has been classified into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.

Hypogammaglobulinemia segment is forecasted for largest market share

The hypogammaglobulinemia segment is the highest contributor to the global market, and is anticipated to maintain its dominance throughout the forecast period. This is mainly attributed to a significant rise in the prevalence of hypogammaglobulinemia disorder across the globe over the years.

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held significant Market share

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held significant market share in the application segment of intravenous immunoglobulin market during the forecast period. It is found in patients with diabetes mellitus. The treatment of CIPD involves the usage of immunosuppressive drugs, plasmapheresis and steroids. IVIG is an effective alternative to these methods. The associated benefits such as safety, minimally invasive and user-friendly treatment option are few other factors contributing towards the development of the industry.

Geographical Analysis

Based on geography, the study analyzes the yeast extract market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America is expected to maintain its dominance in the global intravenous immunoglobulin market through the forecast period. Increasing healthcare expenditure, increasing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and the rising inclination of clinicians towards immunodeficiency therapies are major factors attributing to the market growth. Additionally, growing occurrences of primary immunodeficiency (PID) are also expected to drive market growth in the North American region.

The Asia Pacific is expected to show significant growth during the forecast period due to the increasing awareness and potential opportunities for the adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Furthermore, the growing geriatric population in the region will augment the market growth.

Competitive Landscape

The global intravenous immunoglobulin market is fiercely competitive with the presence of several large and small players operating in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The key intravenous immunoglobulin players which are contributing to the growth of the global market are Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products, Inc., Guizhou Taibang Biological Products Co., Ltd, CSL Limited, Grifols, S.A., Hualan Biological Engineering Inc., Kedrion S.p.A., LFB Group, Octapharma AG.

Bharat Serums and Vaccines Limited

Overview: Bharat Serums and Vaccines Limited is one of the fastest growing bio pharmaceutical companies in India. BSV offers products in the areas of gynecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, hematology, and urology. The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Africa. The Company's specialty is in Injectables, Novel Drug Delivery, R&D, Biologicals, Clinical Research, and Biotech.

Product Portfolio: The company's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins.

Why Purchase the Report?

  • Visualize the yeast extract market segmentation composition by route of administration, clinical trial type phase, application, end user and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the yeast extract market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of yeast extract market - level 4 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global intravenous immunoglobulin market report would provide access to an approx. 60 market data table, 72 figures and 270 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Intravenous Immunoglobulin Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Intravenous Immunoglobulin Market - Market Definition and Overview

3. Global Intravenous Immunoglobulin Market - Executive Summary

  • 3.1. Market Snippet by Route of Administration
  • 3.2. Market Snippet by Clinical Trial Type Phase
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Region

4. Global Intravenous Immunoglobulin Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in primary immune deficiency diseases to drive the intravenous immunoglobulin market
      • 4.1.1.2. Increase in Research and Development
      • 4.1.1.3. Rise in Geriatric Population.
    • 4.1.2. Restraints:
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Intravenous Immunoglobulin Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Intravenous Immunoglobulin Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Intravenous Immunoglobulin Market - By Route of Administration

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
  • 7.3. Market Attractiveness Index, By Route of Administration Segment
    • 7.3.1. Intravenous*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Subcutaneous

8. Global Intravenous Immunoglobulin Market - By Clinical Trial Type Phase

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase Segment
  • 8.3. Market Attractiveness Index, By Clinical Trial Type Phase Segment
    • 8.3.1. Immunoglobulin G*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Immunoglobulin A
    • 8.3.3. Immunoglobulin M
    • 8.3.4. Immunoglobulin E
    • 8.3.5. Immunoglobulin D

9. Global Intravenous Immunoglobulin Market - By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Homecare
    • 9.3.4. Others

10. Global Intravenous Immunoglobulin Market - By Application

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 10.3. Market Attractiveness Index, By Application Segment
    • 10.3.1. Hypogammaglobulinemia*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.3.3. Immunodeficiency Disease
    • 10.3.4. Myasthenia Gravis
    • 10.3.5. Multifocal Motor Neuropathy
    • 10.3.6. Idiopathic Thrombocytopenic Purpura (ITP)
    • 10.3.7. Inflammatory Myopathies
    • 10.3.8. Specific Antibody Deficiency
    • 10.3.9. Guillain-Barre Syndrome
    • 10.3.10. Others

11. Global Intravenous Immunoglobulin Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. Global Intravenous Immunoglobulin Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Intravenous Immunoglobulin Market - Company Profiles

  • 13.1. Bharat Serums and Vaccines Limited*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Biotest AG
  • 13.3. China Biologic Products, Inc.
  • 13.4. Guizhou Taibang Biological Products Co., Ltd
  • 13.5. CSL Limited
  • 13.6. Grifols, S.A.
  • 13.7. Hualan Biological Engineering Inc.
  • 13.8. Kedrion S.p.A.
  • 13.9. LFB Group
  • 13.10. Octapharma AG

LIST NOT EXHAUSTIVE

14. Global Intravenous Immunoglobulin Market - Premium Insights

15. Global Intravenous Immunoglobulin Market - DataM Intelligence

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us